Last verified: April 25, 2026 · Next scheduled review: May 25, 2026

GLP-1 Clinical Trials Tracker 2026: FDA Dates, Phases & NCT IDs

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

This GLP-1 clinical trials tracker is the page we built because the rest of the internet refused to. Two GLP-1 weight-loss approvals landed 13 days apart this spring — Wegovy HD on March 19, 2026, and Foundayo on April 1, 2026 — joining the Wegovy pill that came online in December 2025. Eli Lilly says seven additional Phase 3 readouts for retatrutide alone are expected in 2026. Novo Nordisk has CagriSema sitting at the FDA awaiting a decision. And every other day, a new "research peptide" vendor pops up trying to sell you investigational drugs that aren’t legally available.

Bottom line up front: as of April 25, 2026, three GLP-1 medications have been approved since December 22, 2025 (Wegovy pill, Wegovy HD, Foundayo), one NDA is filed and pending an FDA decision later this year (CagriSema), and at least six Phase 3 programs are reading out through 2026 and 2027. The tracker below is the receipts — every drug, phase, NCT identifier where one exists, FDA status, and the best weight-loss data the manufacturer has actually published.

At a glance: where each major drug stands today

Jump to the full tracker ↓

The GLP-1 clinical trials tracker at a glance

Below is the master tracker. Each NCT identifier links to ClinicalTrials.gov so you can verify recruiting status yourself.

Clinical status can change over time. Verify before treatment or trial decisions.

Approved since December 2025

NDA filed — FDA decision anticipated in 2026

Phase 3 — readouts expected through 2026–2027

Phase 2 (with Phase 3 starting) — worth watching

Adjacent and watch list (not GLP-1, or paused)

What’s already FDA-approved since December 2025

Foundayo (orforglipron) — Eli Lilly

Approved April 1, 2026. Foundayo is the first oral, non-peptide GLP-1 receptor agonist approved for chronic weight management. Unlike Wegovy pill (which is an oral peptide and has to be taken first thing in the morning with limited water and 30+ minutes before food), Foundayo can be taken any time of day, with or without food, with or without water. That sounds like a small detail. For people who’ve struggled to stick to morning fasting windows, it isn’t.

Who it’s right for: People who want a once-daily pill instead of a weekly injection. People who haven’t responded well to oral peptide GLP-1s because the morning-fasting protocol is hard to follow. People who specifically want a non-peptide molecule.

Who it isn’t right for: People with a personal or family history of MTC or MEN2. People who need maximum weight loss — the higher-end injectable GLP-1s (Wegovy HD, Zepbound, and the upcoming retatrutide if approved) report higher efficacy in trials.

Wegovy HD (semaglutide 7.2 mg) — Novo Nordisk

Approved March 19, 2026. Wegovy HD is a higher-dose version of injectable Wegovy — three times the strength of the previously highest dose (2.4 mg). It’s the first GLP-1 approved under the CNPV pilot, with a 54-day review.

Who it’s right for: People who’ve already tolerated standard-dose Wegovy (2.4 mg) for ≥4 weeks and haven’t reached their target weight. People who specifically want semaglutide and don’t want to switch molecules.

Who it isn’t right for: Anyone starting their first GLP-1 — Wegovy HD is a step-up dose, not a starting dose. Given the dysesthesia signal, people with skin-sensitivity concerns or peripheral neuropathy may want to discuss alternatives like Zepbound or wait for forthcoming combination products.

Wegovy pill (oral semaglutide 25 mg) — Novo Nordisk

Approved December 22, 2025. This was the first oral GLP-1 approved for weight loss. It uses semaglutide (the same active ingredient as injectable Wegovy) plus a tablet absorption enhancer that lets the peptide survive digestion.

Who it’s right for: People committed to a strict morning fasting window and who specifically want semaglutide rather than a different molecule.

Who it isn’t right for: Anyone with an irregular morning routine. Foundayo has no food or water restrictions and may be a better fit on logistics alone. See our Wegovy pill vs. Foundayo comparison.

What’s filed and awaiting an FDA decision

CagriSema — Novo Nordisk

CagriSema isn’t a “next-generation GLP-1.” It’s a different idea: combine semaglutide (a GLP-1 agonist) with cagrilintide (a long-acting amylin analog) and let them work on appetite from two different angles at once. Amylin is a hormone secreted alongside insulin from the pancreas; activating amylin receptors in the brain affects satiety through a circuit that’s distinct from GLP-1’s. The result, in trials, is more weight loss than either ingredient alone.

Why it matters: If approved at the 22.7% weight-loss benchmark, CagriSema would land directionally between Zepbound (22.5% in SURMOUNT-1) and the still-investigational retatrutide (28.7% in TRIUMPH-4) — though those numbers come from different trials with different populations. CagriSema would also be Novo Nordisk’s answer to Lilly’s incretin dominance, and the first dual-mechanism injectable approved in obesity.

For the deeper comparison, see our CagriSema vs. retatrutide breakdown and our CagriSema vs. Wegovy guide.

Phase 3 GLP-1 trials reading out in 2026 and 2027

Retatrutide (LY3437943) — Eli Lilly

Retatrutide is the first triple receptor agonist to reach Phase 3 in obesity. It activates GIP, GLP-1, and glucagon receptors all at once. Tirzepatide (Zepbound, Mounjaro) added GIP to GLP-1 and produced ~22% weight loss; retatrutide adds glucagon on top, and so far it’s producing the highest Phase 3 obesity numbers verified in this tracker.

For the full comparison, see our retatrutide vs. tirzepatide breakdown and our triple agonist vs. dual agonist guide.

Survodutide (BI 456906) — Boehringer Ingelheim / Zealand Pharma

Survodutide is a dual GLP-1 + glucagon agonist. It pairs GLP-1’s appetite suppression with glucagon’s effects on energy expenditure and hepatic fat clearance — a profile that’s particularly interesting for liver disease alongside obesity.

MariTide (maridebart cafraglutide) — Amgen

MariTide breaks the mold in two ways. First, it’s a peptide-antibody conjugate — a GIP-receptor antagonist antibody linked to two GLP-1 agonist peptides. Second, its half-life is roughly 21 days, which means once-monthly (or less frequent) dosing — one of the most advanced less-frequent-dosing programs in the obesity pipeline.

Why it matters: Dosing burden is one of the biggest reasons people drop GLP-1s. A monthly injection — or potentially less frequent — could meaningfully change adherence. MariTide is also Amgen’s first major obesity bet.

VK2735 — Viking Therapeutics

Dual GLP-1 + GIP agonist. Both subcutaneous (Phase 3) and oral (Phase 2) formulations under development. The Phase 3 VANQUISH program is a 78-week, randomized, double-blind, placebo-controlled study with ~4,500 participants and an estimated completion date of August 2027. Phase 2 SC data showed up to -14.7% weight loss at 13 weeks — striking for that duration. Viking recently announced enrollment completion for VANQUISH-2.

Why it matters: Same mechanism as tirzepatide (Zepbound) but a different molecule, and Viking is moving fast. If Phase 3 confirms Phase 2 efficacy, VK2735 could become the first non-Lilly tirzepatide-class option.

Phase 2 and earlier — drugs worth watching

These won’t be available to the public soon. But they’re the candidates most likely to become the post-2027 standard of care, and several are recruiting clinical trial participants right now.

PF’3944 (MET-097i) — Pfizer

Long-acting injectable GLP-1 agonist designed for monthly maintenance dosing. Phase 2b VESPER-3 reported up to -12.3% placebo-adjusted weight loss at 28 weeks, with weight loss continuing after a planned switch from weekly to monthly dosing. Pfizer has stated that 10 Phase 3 trials are expected to advance in 2026, with 20+ ongoing or planned studies across its broader obesity pipeline.

Aleniglipron (GSBR-1290) — Structure Therapeutics

Once-daily oral, small-molecule GLP-1 agonist (similar mechanism to Foundayo, different molecule). The March 2026 ACCESS II readout showed up to 16.3% placebo-adjusted weight loss at 44 weeks at the 180 mg dose. Phase 3 is planned for H2 2026 following the FDA end-of-Phase 2 meeting in Q2 2026. A second oral non-peptide option drives pricing pressure.

Amycretin — Novo Nordisk

A unimolecular dual GLP-1 + amylin agonist — same combination as CagriSema, but in one molecule instead of two. Both oral and subcutaneous formulations are in development. Phase 3 program initiated Q1 2026. Early data: up to -24.3% weight loss over 36 weeks in adults without diabetes; up to -14.5% SC and -10.1% oral in T2D.

Eloralintide (LY3841136) — Eli Lilly

Lilly’s amylin analog — its second obesity pipeline bet alongside retatrutide. Phase 3 program registered on ClinicalTrials.gov: NCT07282600, NCT07321886, and NCT07369011.

Pemvidutide (ALT-801) — Altimmune

Dual GLP-1 + glucagon agonist with FDA Fast Track for MASH and AUD, and Breakthrough Therapy designation for MASH. More of a liver/metabolic-disease candidate than a mainstream obesity drug at this point.

How these drugs actually differ (by mechanism)

Ranked: highest weight loss reported in GLP-1 trials

Should you wait for a new GLP-1 — or start now?

The decision tree

How to find a GLP-1 clinical trial near you

Step 1 — Search by the drug’s generic name

Search ClinicalTrials.gov by: retatrutide, maridebart cafraglutide (or “MariTide”), survodutide, VK2735, amycretin, eloralintide, aleniglipron (or “GSBR-1290”), pemvidutide, cagrilintide semaglutide (or “CagriSema”).

Filter: Status: Recruiting · Phase: Phase 3 (or Phase 2 if open to earlier-stage) · Map view filtered to your distance.

Step 2 — Save the NCT number

Every legitimate US-registered study has an NCT number on ClinicalTrials.gov. Save it. The NCT page is your anchor for verification, and the coordinator will ask you to reference it.

Step 3 — Use the manufacturer’s trial finder for current site status

Site-level recruiting status changes faster than the registry. The most reliable secondary source is the manufacturer’s trial-finder portal:

Step 4 — Call the coordinator (script you can copy)

“Hi, I’m interested in study [NCT number]. Are you currently enrolling at this site? Can you tell me about the major eligibility criteria, the visit requirements, whether the study includes placebo or an active comparator, the compensation and travel reimbursement policy, and any restrictions related to recent or current weight-loss medication use?”

Step 5 — Don’t stop a current medication to qualify

Some GLP-1 trials exclude recent weight-loss medication use, and some use 90-day washout windows — the exact rule depends on the protocol. Don’t stop a prescribed medication just to qualify unless your prescribing clinician agrees it’s safe and appropriate.

How do you know if you qualify?

Eligibility depends on the specific protocol. Trials typically define age, BMI, diagnosis, medication history, recent weight change, lab values, pregnancy status, and medical exclusions.

Common factors:

• Age range (most adult obesity trials enroll 18+; some go to 75 or beyond)
• BMI threshold (most obesity-only trials require BMI ≥30; some include BMI ≥27 with comorbidity)
• T2D status (some trials are diabetes-only, some are non-diabetes-only)
• Stable weight period before screening
• Recent weight-loss medication use (often a washout period required)
• Pregnancy or breastfeeding (typically excluded)
• Specific medical history exclusions — personal or family history of medullary thyroid carcinoma is often a categorical exclusion

Are GLP-1 clinical trials paid?

Some GLP-1 trials provide compensation for study visits, time, and travel — but compensation varies widely and shouldn’t be your primary reason to enroll. Investigational medication is typically provided at no cost during the trial.

What to ask: Is there per-visit compensation? Are travel and parking reimbursed? Are study-related labs and imaging covered? What happens if you experience a side effect requiring care outside the trial?

Will I get placebo? What about randomization?

Most Phase 3 GLP-1 obesity trials are randomized, placebo-controlled, and double-blind — neither you nor your study clinician knows which arm you’ve been assigned to. Some trials include an active comparator (e.g., TRIUMPH-5 retatrutide vs. tirzepatide). Ask the coordinator for the randomization ratio and whether there’s an open-label extension after the placebo-controlled phase ends.

When a clinical trial isn’t the right path

• You need treatment immediately — trial screening can take 4–12 weeks
• You’ve used a GLP-1 recently — many trials have washout requirements
• You’re in a rural area without a study site within driving distance
• You can’t take time off work for the visit cadence (ask the coordinator for the exact schedule)

How to spot a real clinical trial vs. gray-market “research peptides”

If you’ve searched “GLP-1 clinical trials” recently, you’ve probably also seen ads or social posts offering retatrutide, CagriSema, or tirzepatide for sale online — sometimes branded as “research grade” or “for research use only.” Those aren’t trials. Many aren’t even legal sales of approved drugs.

What to do if you’ve already bought or used one of these products

We’re not going to lecture you. People are stuck and trying to find a path forward.

• Don’t rely on online dosing forums. The dose, sterility, and even the actual active ingredient may be different from what you think
• Tell a licensed clinician what you used, where it came from, the dose, and how long you’ve been on it. Most clinicians will work with you without judgment
• If you have severe abdominal pain, persistent vomiting, allergic symptoms, fainting, chest pain, or other urgent symptoms — seek medical care immediately and bring the product packaging

How we built this tracker

Our evidence confidence ladder

What gets refreshed and how often

Frequently asked questions

The bottom line

The 2026 GLP-1 pipeline is the most active obesity drug pipeline in the history of medicine. Three approvals in the past four months, one decision pending later this year, six Phase 3 programs reading out, and a deeper bench of Phase 2 candidates than the field has ever seen.

The catch: most of those drugs aren’t available to you yet. Some won’t be approved until 2027 or later. Some won’t be covered by your insurance for 12–18 months after approval. And the gray-market shortcuts being marketed online aren’t shortcuts — they’re risk dressed up as access.

Here’s what we’d do in your position:

1. Use the tracker above to know exactly what’s approved, what’s filed, and what’s still investigational
2. If you have a current obesity-related condition, talk to a clinician about an approved option now
3. If you’re considering a clinical trial, use the steps in How to find a trial near you and verify the NCT before doing anything else
4. If you don’t know which path is right, take our matching recommendation below

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Clinical trial status, drug availability, FDA decisions, and efficacy data can change. Always verify current status and discuss any treatment or trial enrollment decision with your licensed prescribing clinician.